T he provision of opioid agonists like buprenorphine/naloxone constitutes a highly effective, evidence-based treatment for opioid use disorder (Mattick et al., 2014) . Many regulations governing the provision of buprenorphine/naloxone therapy in the United States have been put into place for purposes of diversion control (Jaffe and O'Keeffe, 2003; Piper et al., 2016) . Concerns about the potential for medication diversion continue to act as barriers to the scale up of opioid agonist treatment in various clinical and criminal justice settings (Nunn et al., 2009; Hutchinson et al., 2014) . A large body of qualitative, quantitative, and mixed-methods research indicates that the diversion of buprenorphine/naloxone medication, when it occurs, is overwhelmingly undertaken for purposes of self-treatment-to treat symptoms of opioid withdrawal or as self-initiated treatment for opioid use disorder (Gwin Mitchell et al., 2009; Genberg et al., 2013; Havnes et al., 2013; Richert and Johnson, 2013; Allen and Harocopos, 2016) . This trend was observed to hold true in the state of Rhode Island in 2009, when a study found 84% of opioid injectors who reporting diverted buprenorphine/naloxone use claimed to have sought the diverted medication for selftreatment purposes (Bazazi et al., 2011) .
Much has changed in Rhode Island's illicit opioid market since this study in 2009. Most notably, fentanyl, a synthetic opioid many times stronger than morphine (estimated 100 morphine milligram equivalents when delivered parenterally; McPherson, 2009) , is believed to have entered the illicit opioid market in Rhode Island in early 2013, as indicated by first an outbreak of acetyl fentanyl overdose deaths in the spring (Lozier et al., 2015) . This was followed by a dramatic increase in fentanyl-involved opioid overdose fatalities during that year (Mercado-Crespo et al., 2014) . Concurrent with the entrance of fentanyl into local drug markets in Rhode Island, changes in drug use behaviors, including novel risk mitigation factors (taking test hits, smelling or visually scrutinizing opioid products for evidence of contamination, and the leveraging of trusting interpersonal relationships to reduce the likelihood of contamination), have been reported by people who use illicit or diverted prescription opioids in Rhode Island . The prevalence of fentanyl-contaminated opioid products also has implications for the pharmacological treatment of opioid use disorder, as the heightened opioid tolerance generated by fentanyl exposure may complicate the establishment of a ''blocking'' dose of opioid agonist medication, which would extinguish illicit use (Stone et al., 2017) . Given the serious threat fentanyl poses, the scale up of opioid agonist treatments (methadone and buprenorphine/naloxone) has become a major public health priority in many parts of the United States, including Rhode Island (Rhode Island Governor's Overdose Prevention and Intervention Task Force, 2015) . Therefore, an understanding of how these developments in the drug market and concurrent changes in patterns of drug use have affected trends in buprenorphine/naloxone diversion is needed in order to balance the public health risks and benefits of expanding this form of care.
This study analyzes survey data collected in Rhode Island in 2016, which describe patterns of and motivations for buprenorphine/naloxone diversion by people who use illicit opioids and compares that data to findings from a study carried out among a similarly recruited population by Bazazi et al in 2009 (Bazazi et al., 2011 , providing a picture of how the illicit diversion of this medication for opioid use disorder has changed since the introduction of fentanyl into the local drug market.
METHODS
Subject recruitment and data collection for this study have been described elsewhere . In brief, subjects who met established eligibility criteria-over 18 years old, residing in Rhode Island, and reporting nonmedical opioid use in the previous 30 days-were recruited from direct service points, such as syringe access programs and outreach organizations, in Providence, Rhode Island, between January 1 and November 30, 2016. Consenting participants completed a questionnaire designed to capture demographic information as well as personal details related to substance use, overdose, medication diversion, naloxone access, and health care access. Participants were offered $10 compensation for completing the questionnaire.
Descriptive statistics were generated for all demographic information, as well as employment, housing, incarceration history, patterns of substance use, and history of overdose. A second set of descriptive statistics was generated to describe patterns of buprenorphine/naloxone diversion, including history of use, common sources, motivations for use, and experience seeking buprenorphine/naloxone-based treatment in a clinical setting. Logistic regression was used to calculate odds ratios (ORs) of demographic and behavioral variables to identify correlates of lifetime use of diverted buprenorphine/naloxone as well as use of diverted buprenorphine/naloxone in the past 2 months.
The questionnaire used in this study was designed, in part, to mirror the content of a questionnaire distributed among a similarly defined and recruited population in Providence, Rhode Island by Bazazi et al, in 2009 (Bazazi et al., 2011 for the express purpose of making these 2 datasets comparable. Descriptive statistics for the population in this study were compared with those from the 2009 study, which also explored buprenorphine/naloxone diversion among people who use opioids non-medically in Providence, Rhode Island. This research was approved by the Institutional Review Board at the Miriam Hospital in Providence, Rhode Island.
RESULTS
A total of 128 adult residents of Rhode Island reporting recent non-medical opioid use participated in the 2016 study (Table 1) . Of these, 67% (n ¼ 81) identified as male. More than 75% (n ¼ 100) reported a history of incarceration, and 21% (n ¼ 26) did not have stable housing at the time of their participation in this study. Heroin was the most commonly used drug within this sample population, with 71% of participants (n ¼ 84) reporting use at least weekly, followed by prescription opioids at 38% (n ¼ 44) and cocaine at 34% (n ¼ 42). The majority of participants (58%, n ¼ 73) reported some form of non-medical opioid use at least 5 days per week. Compared to the cohort sampled by Bazazi et al in 2009 , members of the 2016 cohort were less likely to be white (52% vs 81%), were less likely to be unemployed (50% vs 93%), reported lower rates of homelessness (21% vs 52%), and reported greater rates of past history with non-fatal opioid overdose (34% vs 24%).
Individuals in the 2016 cohort reported similar rates of both lifetime and recent use of diverted buprenorphine/naloxone to those observed in the 2009 cohort, with 73% versus 76% reporting lifetime use, respectively, and 38% versus 41% reporting recent use, respectively (Table 2) . Methods for obtaining diverted buprenorphine/naloxone also appear relatively similar between the 2 groups. In the 2016 cohort, 39% of participants (n ¼ 28) reported obtaining the diverted medication from friends, compared to 32% (n ¼ 24) in the 2009 cohort. Other common sources identified in this study include acquaintances (26%, n ¼ 18) and regular dealers (17%, n ¼ 12).
Rates of reported motivations for using diverted buprenorphine/naloxone differed between the 2 cohorts. Generally speaking, members of the 2009 cohort frequently selected >1 motivation, whereas members of the 2016 cohort typically selected only 1, despite having the opportunity to endorse as many motivations as they wished. Among both cohorts, the most commonly reported motivations for the use of diverted buprenorphine/naloxone were the management of withdrawal symptoms (40%, n ¼ 35, in 2016; 74%, n ¼ 56, in 2009) and self-treatment of opioid use disorder (39%, n ¼ 34, in 2016 vs 74%, n ¼ 56 in 2009). Given these proportions, the 2016 cohort appeared to report use of diverted buprenorphine/ naloxone for the purpose of ''getting high'' (12%, n ¼ 4) less frequently than did the 2009 cohort (47%, n ¼ 36).
In bivariate analysis, age, gender, and ethnicity were not found to be significantly associated with lifetime use of diverted buprenorphine/naloxone in the 2016 study (Table 3) Individuals who had sought a medical prescriber to provide buprenorphine/naloxone-based treatment for opioid use disorder in the past 12 months had a significantly higher odds of having used diverted buprenorphine/naloxone in their lifetime (OR ¼ 3.18, 95% CI ¼ 1.02-9.98, P ¼ 0.05) and of having used diverted buprenorphine/naloxone in the past 2 months (OR ¼ 5.14, 95% CI ¼ 1.00-26.5, P ¼ 0.05). Several measures of experience with opioid overdose and fentanyl exposure were correlated with lifetime use of diverted buprenorphine/naloxone, but none correlated with use of diverted buprenorphine/naloxone in the past 2 months.
Participants in this study reported lower rates of buprenorphine-based treatment seeking (25%, n ¼ 35) and successful initiation of buprenorphine-based treatment (3%, n ¼ 4) than those surveyed in 2009 (41%, n ¼ 41, and 18%, n ¼ 18, respectively). Both study populations reported similar lifetime barriers to buprenorphine-based treatment. In this study, 51% (n ¼ 22) reported the inability to locate a provider who did not have a waitlist for buprenorphine-based care compared to 49% (n ¼ 48) in 2009. Similarly, 23% (n ¼ 10) reported the cost of treatment, plus an additional 23% (n ¼ 10) reporting lack of insurance coverage for buprenorphine-based treatment, as a barrier to care, compared to 49% (n ¼ 49) who reported treatment-associated costs as a barrier to care in 2009.
DISCUSSION
This study distributed a questionnaire to adults in Rhode Island who reported regular non-medical use of opioids to explore current patterns of buprenorphine/naloxone diversion and use. The use of diverted buprenorphine/naloxone appeared to be common among the 2016 cohort, with most having used the diverted medication at least once in their lives and nearly half reporting recent use. Correlates of lifetime use of diverted buprenorphine/naloxone included regular heroin use, and a personal history of witnessing or experiencing an opioid overdose-both of which may be proxy indicators of more severe opioid use disorder. Taken together, this study and the study conducted by Bazazi et al in 2009 present a picture of buprenorphine diversion among the non-medical opioid using community in Providence, Rhode Island, before the emergence of fentanyl in the local drug market and after fentanyl-contaminated product became so prevalent that avoidance was often impossible (Mercado-Crespo et al., 2014; Carroll et al., 2017) .
Though the 2016 cohort was relatively better off than the 2009 cohort (ie, reporting lower rates of homelessness and unemployment), rates of diverted buprenorphine/naloxone use were similar between the 2 groups, as were commonly reported barriers to buprenorphine/naloxone-based treatment for opioid use disorder. Forms of self-treatment were the most commonly reported motivation for use of the diverted medication in both groups; however, participants in the 2009 cohort were more likely to report using buprenorphine/naloxone to ''get high'' (the language used in both survey instruments) than those in the 2016 cohort. This may be due to increased use of diverted buprenorphine/naloxone as a riskreduction strategy by people who use opioids who fear for their safety in a fentanyl-contaminated drug market, as qualitative data collected from this cohort (published elsewhere) suggests . Alternatively, changes in the availability of more desirable opioid products may have led those who are seeking a strong euphoric effect away from diverted buprenorphine/naloxone for that purpose (Comer et al., 2008) . Finally, it is also noteworthy that seeking a medical provider to prescribe buprenorphine/naloxone was significantly associated with the use of diverted medication in 2016 at a time when fewer individuals were seeking treatment to begin with, and almost none were able to access treatment with buprenorphine/naloxone. It is particularly distressing that in 2016, when pharmacotherapies for opioid use disorder have been heralded as a cornerstone in the fight against opioid overdose across the United States (Cropsey et al., 2013; Hawk et al., 2015 ; Rhode Island Governor's Overdose Prevention and Intervention Task Force, 2015; Brinkley-Rubinstein et al., 2017) . Rhode Island has recently undertaken efforts to increase access to buprenorphine/naloxone treatment, including making medications for addiction treatment available in correctional institutions , creating Centers of Excellence, and promoting DATA waiver training for physicians to prescribe buprenorphine/naloxone. According to current measures, the number of Rhode Islanders receiving this form of care grew only marginally from 4337 in 2015 to 4636 in 2017; though it is possible that the significant increase in medications for addiction treatment provision in Rhode Island correctional institutions may not yet be sufficiently captured by state statistics, this count remains far short of the stated goal of 6500 (Rhode Island Governor's Overdose Prevention and Intervention Task Force, 2018). Furthermore, the findings of this study indicate that the nature and the severity of barriers to treatment reported by people using opioids nonmedically in Rhode Island were no different in 2016 than they were 7 years prior. Known causes of disparities in access to buprenorphine/naloxone treatment in the United States include prescriber shortages, systemic financial and institutional barriers, and widespread concern for the public health risks posed by medication diversion (Duncan et al., 2015) . In this study, we asked participants about use within the past 2 months. Bazazi et. al. asked participants about use in the past 30 days. yOnly the final 35 participants in this study were asked when they used diverted buprenorphine most recently. 34 of these 35 participants responded to the question. zIn this study, we asked participants what barriers to buprenorphine treatment they had experienced in the past year. Bazazi et al asked participants why they were not receiving buprenorphine treatment at the time of the survey.
Stigma against the use of medications in the treatment of opioid use disorder also remains strong even within large segments of the addiction medicine community (Molfenter et al., 2015) , and it continues to rear its head in the form of abstinence-only treatment programs, the removal of children by social service agencies from parents who are on medications, and judges refusing to provide patients with opioid use disorder on bond unless they cease their medication (Sharfstein, 2018) . Public health and health care professionals must do more to help the public and policy makers understand the life-saving potential of medications for the treatment of opioid use disorder. As US Food and Drug Administration Commissioner Scott Gottlieb recently testified: patients doing well on medications ''should [be considered] role models in the fight against the opioid epidemic'' (Sharfstein, 2018) .
The widespread disinclination to offer buprenorphine/ naloxone treatment due to stigma-driven concern of medication diversion appears particularly ironic next to the findings of this study, in which treatment-seeking among those using opioids is positively correlated with the use of diverted treatment medications. Whether diverted medications are stimulating interest in physician-supervised treatment or whether those who use opioids are resorting to self-treatment following the inability to access clinical care remains unclear from this and other studies . Future studies should examine the strength of this potential push-pull effect between clinic-based treatment and self-treatment with diverted medications. That the significant expansion of buprenorphine/naloxone-based treatment for opioid use disorder is the logical response to both of these possibilities, however, is undeniable.
Though no single study can be conclusive, this study provides yet another data point in the growing body of evidence that systematic barriers to treatment and, as a result, inadequate treatment capacity for those with opioid use disorder, is largely responsible for perpetuating today's black (Meehan, 2015) , yet nearly half of the counties in the state do not have a DATAwaivered physician authorized to prescribe buprenorphine/ naloxone practicing within its borders (Myers and Borders, 2016) . A similar panic about rising rates of medication diversion is growing in Ohio, prompting some news outlets to refer to the clinics providing life-saving buprenorphine/ naloxone treatment as ''Ohio's new 'pill mills''' (Price and Schladen, 2017) . Nevertheless, access to clinic-based buprenorphine/naloxone treatment in Ohio remains very limited, with fewer than 400 physicians in the entire state are actively prescribing and nearly half of those do not accept insurance payments (Parran et al., 2017) . Black markets for diverted buprenorphine/naloxone appear to be flourishing in the absence of reasonable access to prescribed medication. If this is the case, the key to controlling buprenorphine/naloxone diversion does not lie in more stringent regulation, but rather in the broad loosening of diversion control measures, which discourage physicians from providing buprenorphine/naloxone-based care in the first place. These findings should be interpreted with certain study limitations in mind. Similar diversion patterns may not be observed among people who use opioids non-medically beyond Rhode Island. Additionally, it is possible that patterns of diversion, opioid-seeking, and treatment-seeking have continued to evolve in the Providence region, potentially limiting the applicability of these data to current policy or public health efforts (Rhode Island Governor's Overdose Prevention and Intervention Task Force, 2016). One hundred twenty-eight people using opioids non-medically participated in this study, and even fewer were surveyed for data regarding recent buprenorphine/naloxone diversion. Additionally, due to its cross-sectional design, this study provides a snapshot of diversion and treatment seeking patterns; the chronology of exposure and outcome development is not entirely clear. Finally, participants in this study were recruited from direct-service points or by recommendation from staff at those organizations. Thus, findings may not be generalizable to individuals using opioids non-medically who are not interfacing with community organizations or those who are of a higher or lower socio-economic status than the individuals surveyed here.
CONCLUSIONS
Rates of diverted/buprenorphine use do not appear to have changed throughout the introduction and growth of a fentanyl contaminated drug market in Rhode Island. Motivations for use of this diverted medication do appear to have changed, with fewer people using opioids reporting seeking buprenorphine/naloxone in order to ''get high'' in 2016 compared to 2009 . Associations between use of diverted medication and unsuccessful treatment seeking indicate a severe and potentially life-threatening shortage in treatment capacity and access in this region. Though concerns about buprenorphine/naloxone diversion may be discouraging physicians from providing this form of care, high rates of medication diversion seem to indicate that increased treatment capacity is precisely what is needed most.
